About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width

Clinicaltrials.gov identifier NCT03926975

Recruitment Status Completed

First Posted April 25, 2019

Last update posted January 29, 2021

Study Description

Brief summary:

The purpose of this study is to evaluate the use of two instruments to measure changes in two ocular structures: 1) the anterior chamber depth (ACD) - measured using low coherence optical biometry, and 2) minimum rim width of the optic nerve head (MRW) - measured using optical coherence tomography. Changes in these ocular structures indicate fluctuations in intraocular pressure (IOP) and will be measured during scleral contact lens (SGP) wear to determine if SGP wear influences IOP. We hypothesize that a scleral lens increases the intraocular pressure (IOP) during active wear and that the ACD and MRW will also change.

  • Condition or Disease:Ocular Hypertension
  • Intervention/Treatment: Device: Scleral Lens
    Other: No lens
  • Phase: N/A
Detailed Description

Contact lenses are often used to correct vision blur. The most common types of contact lenses include those referred to as 'soft' and 'rigid'. Visual acuity through rigid lenses often surpasses that of soft lenses. Historically, these lenses have been small in diameter, and hence patients also felt discomfort when wearing the lenses. Scleral lenses are relatively new, customized devices that have gained popularity with patients and practitioners in the past 5-10 years, because they are more comfortable and provide more stable vision than the small diameter rigid contact lenses. However, relatively little is known about the physiologic response of the eye to the scleral lens, or the long-term effects of their use, since they are such a new modality. Maintaining the IOP within the eye is imperative to prevent damage to ocular tissue, which can occur in glaucoma. Given the landing of scleral lens overlying the sclera and ciliary body, which assist in modulating the transport of fluid in the eye, there is a potential for these lenses to impinge on fluid drainage which could lead to increases of IOP during scleral lens wear. The placement of the lens creates an obstacle in evaluating IOP while the lens is actually on the eye (covering the cornea), and since increases in IOP may only occur during lens wear, which is removed when determining clinical IOP measurements, it is difficult to monitor IOP during scleral lens wear with traditional IOP instrumentation (ie. iCare, Goldman, etc). Optical coherence tomography is a non-invasive imaging technology that has revolutionized how the retina and optic nerve are clinically evaluated. The optic nerve head is typically assessed using radial scans, from which the minimal distance from the Bruch's membrane opening to the inner limiting lamina is quantified as the minimum rim width (MRW). With changes in IOP, the MRW is known to also change in thickness. Many studies are investigating the MRW changes during IOP fluctuations, with studies finding a decrease in MRW during acute IOP increase. In this project, MRW will be used to indirectly assess changes in IOP by measuring the MRW periodically during active scleral lens wear. In addition, we are incorporating low coherence optical biometry (Lenstar) to evaluate the effect of the scleral lens pressure on the anterior chamber. Using the Lenstar, corneal thickness, anterior chamber depth (ACD), lens thickness and vitreous chamber depth can be quantified. In this project, ACD will be used to indirectly evaluate changes in the pressure within the anterior chamber. The assumption is that the ACD will change based on changes in pressure in the scleral lens tear reservoir. This study will add to the knowledge of how the scleral lens affects the dynamic pressure system of the eye. Based on the implications for disease with chronic increases and fluctuations in IOP, this is important information to understand with the scleral lens, a relatively new refractive treatment modality.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 26 participants
  • Allocation: Randomized
  • Intervention Model: Single Group Assignment
  • Intervention Model Description: Subjects are all non-scleral lens wearers. One eye (test) will be selected to wear a scleral lens, and the contralateral eye (control) will not wear any lens.
  • Masking: None (Open Label) ()
  • Primary Purpose: Basic Science
  • Official Title: The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width
  • Actual Study Start Date: June 2018
  • Actual Primary Completion Date: June 2019
  • Actual Study Completion Date: August 2019
Arms and interventions
Arm Intervention/treatment
Experimental: Experimental: Scleral Lens
One eye will be randomly selected to wear a scleral lens for a 6-hour testing period.
Device: Scleral Lens
The contact lens will be worn on one eye.
Active Comparator: Control: no lens
The contralateral eye will not wear a lens.
Other: No lens
No lens worn on the contralateral control eye
Outcome Measures
  • Primary Outcome Measures: 1. Change in minimum rim width from baseline to 6-hours SL wear [ Time Frame: at baseline, after 2-hours lens wear, and after 6-hours lens wear ]
    The Bruch's membrane opening to the inner limiting lamina (termed the minimum rim width) will be measured at the optic nerve head.
  • Secondary Outcome Measures: 1. Intraocular pressure (IOP) [ Time Frame: at baseline, after 2-hours lens wear, and after 6-hours lens wear ]
    IOP will be measured using the Diaton and iCare tonometers
  • 2. Anterior Chamber Depth (ACD) [ Time Frame: at baseline, after 2-hours lens wear, and after 6-hours lens wear ]
    ACD will be measured with the Lenstar A-scan
Eligibility Criteria
  • Ages Eligible for Study: 18 to 60 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- young, normal individuals

Exclusion Criteria:

- IOP > 20mm in either eye, and h/o ocular hypertension, glaucoma, or ocular surgery
that can affect IOP.

- h/o scleral lens wear or current scleral lens wear

Contacts and Locations
Contacts
Locations

United States, Texas
University Eye Institute
Houston

Sponsors and Collaborators

University of Houston

Investigators

Principal Investigator: Maria Walker University of Houston

More Information
  • Responsible Party: University of Houston
  • ClinicalTrials.gov Identifier: NCT03926975 History of Changes
  • Other Study ID Numbers: STUDY00000747
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: January 29, 2021
  • Last Verified: January 2021
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: Yes
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Ocular Hypertension